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Abstract,  PDGF is a powerful mitogen initially iden- 
tiffed within platelets, but also shown to be produced 
by a wide variety of cell types. PDGF is encoded on 
two separate genes. These give rise to three polypep- 
tides, PDGF B and twoforms of PDGF A (SA and 
LA), resulting from alternative splicing of the PDGF A 
gene primary transcript. We report that in CHO cells 
transfected with PDGF gene constructs and producing 
moderate levels of PDGF homodimers, much of the 
PDGF LA and B produced, but little if any SA,  is 
found in the matrix laid down beneath the ceils. 
Immunoreactive PDGF in cells, and in matrix below 
expressing cells, was visualized by laser confocal 
microscopy. Western blotting of protein in matrix 
extracts, cell extracts, and secreted into the growth 
medium was used to demonstrate that the range of 
PDGF A polypeptides seen in the matrix was overlap- 
ping with those reported previously to be cell associ- 
ated in cell types such as NIH3T3  and COS 7. This 
suggests  that attachment to matrix or cell surface may 
be alternative fates for these polypeptides, with fate 
dependent on the characteristics of the producing cells. 
Immunoreactive PDGF A and B could be partially 
released by incubation of matrix material with heparin 
but not with other glycosaminoglycans. Digestion of 
matrix with chondroitin ABC lyase but not hepariti- 
nase or collagenase displaced some PDGF from its 
attachment sites.  The results indicate attachment of 
PDGF to matrix proteoglycans, at least partly through 
the glycosaminoglycan moieties, and perhaps to addi- 
tional components. The significance of matrix deposi- 
tion for PDGF action is discussed. 
p 
DGF is a mitogenic growth factor isolated from plate- 
lets, where it is found primarily as a heterodimer of 
A and B chains (reviewed in Ross et al., 1986; Heldin 
and Westermark,  1990). The A and B polypeptides, which 
are encoded by separate genes, are two members of a family 
of related polypeptides, which also includes vascular endo- 
thelial cell growth factor (VEGF,  t VPF; Keck et al., 1989; 
Leung et al.,  1989), a recently  described placental  factor 
(Maglione et al., 1991), and a connective tissue growth fac- 
tor produced by vascular endothelial cells (Bradham et al., 
1991). 
Molecular cloning of the PDGF A and B genes has been 
reported by several groups (Betsholtz et al., 1986; Rao et al., 
1986). Alternative splicing of the PDGF A gene transcript 
(Tong et al., 1987; Collins et al., 1987; Sfmchez  et al., 1991) 
results in the production of at least two functional polypep- 
tides. The most common form of PDGF A mRNA lacks the 
gene's sixth exon and encodes  a  196  amino  acid  form of 
PDGF A (SA). Expression of the SA gene in cell types such 
as 3T3 and COS 7 results in the production of a homodimer 
of molecular weight 30 kD which is predominantly secreted 
1. Abbreviations  used in this paper: HSPG, heparan sulfate proteoglycan; 
VEGF, vascular endothelial cell growth factor. 
from the cells. An alternative mRNA includes an additional 
exon and encodes a PDGF A polypeptide of211 amino acids, 
LA. This polypeptide  has been  reported  to be much less 
efficiently  secreted  than  the  SA  product,  The  extended 
COOH terminus of the LA polypeptide includes a stretch of 
very basic amino acids. In recent reports,  it has been sug- 
gested that in cell types such as NIH 3T3, PDGF LA mole- 
cules remain attached to cells via this additional basic re- 
gion. An analogous sequence in the COOH terminal region 
of PDGF B appears to explain why some processing prod- 
ucts of this protein are cell-attached  (Ostman et al.,  1991; 
LaRochelle et al.,  1990a). 
It  has  recently  been  reported  that  cellular  binding  of 
PDGF can be blocked (Khachigian et al.,  1992) and cell- 
bound PDGF released from cells (Raines and Ross, 1992) 
by the basic peptide from the COOH terminus of  PDGF LA. 
Binding of PDGF polypeptides to cell-surface heparan sul- 
phate proteoglycan  (HSPG) via this basic  amino  acid  se- 
quence has been proposed  (Raines and Ross, 1992; Kha- 
chigian et al.,  1992; Khachigian and Chesterman,  1992). 
In contrast  with results reported  for 3T3  and other cell 
types, a report on PDGF expression in CHO cells found little 
evidence for surface localization or major cell association of 
P~F,  .Tlayberg  et al. (1990) described localization of small 
anaQtlnts of PDGF BB in the Golgi, lysosomes, and ER of 
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levels, and in locations consistent with packaging of the pro- 
tein for secretion. In this report, we demonstrate that PDGF 
LA produced by CHO cells is predominantly deposited into 
extracellular matrix beneath the cells, with relatively little 
cell-associated material being found. In CHO cells express- 
ing PDGF B, substantial amounts of this homodimer are also 
associated with matrix material, while PDGF SA is secreted 
into the growth medium as in other cell types. 
Materials and Methods 
PDGF Gene Isolation and Vector Construction 
PDGF SA, LA, and B coding regions were isolated by polymerase chain 
reaction amplification from cellular RNA as described previously (S~lnchez 
et at., 1991). The genes were then inserted into expression vectors to allow 
inducible expression in mammalian cells. The vectors used were derived 
from pSVL (Pharmacia-LKB,  Uppsala, Sweden), a vector which includes 
the SV-40 late promoter and splice region and SV-40 polyadenylation sig- 
nals, together with plasmid sequences to allow replication in Escherichia 
cold and antibiotic selection, pSVL was first treated to remove NaeI sites 
within pBR322 sequences, as shown in Fig. 1. Subsequently,  the SV-40  pro- 
moter was removed  and the promoter from the human metallothionein IIA 
gene, contained on a BgllI fragment excised from pMetCAT (McNeall et 
al., 1989) was inserted at the cut site (Fig. 1). PDGF coding sequences were 
inserted into the polylinker region of  the vector, as shown in Fig. 1, to yield 
the vectors pMetPDGF-SA, pMetPDGF-LA, and pMetPDGF-B. 
Cell Culture and Transfection Procedures 
CHO K1 cells were routinely cultured in a  1:1 mixture of DME and Ham's 
FI2 medium containing 10% FCS, as described previously (McNeaU et al., 
1989). For induction and collection of secreted protein, cells were trans- 
ferred to serum-free medium. Expression of inserted genes under control 
of the metallothionein promoter was induced by addition to the medium of 
cadmium chloride (1 #M) and zinc chloride (50 ~M) for 18 h before cell 
harvest. 
CHO cells were transfected with DNA by calcium phosphate co-precipi- 
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Figure 1. Construction  of  metal- 
inducible expression  vectors 
containing PDGF genes. The 
vectors used were derived from 
pSVL (Pharmacia-LKB) which 
contains the  SV-40  late pro- 
meter and  splice region fol- 
lowed by a polylinker and SV- 
40  polyadenylation  region. 
Excess NaeI sites in pBR322 
sequences were removed by de- 
letion of the NaeI to XmalII 
535-bp fragment to yield the 
plasmid pSVLN. This was sub- 
sequently digested with NaeI 
and SfiI; mung bean nuclease 
digestion was used to generate 
blunt  ends  (Maniatis et  al., 
1982). This vector was ligated 
to a 562-bp fragment contain- 
ing the human metallothionein 
HA promoter.  The  fragment 
was generated by BgllI diges- 
tion of pMet CAT (McNeall et 
al., 1989) followed by Klenow 
DNA polymerase  I to generate 
blunt ends.  The  vector gen- 
erated  after  ligation,  pMet, 
was  the  recipient for coding 
sequences  from  the  genes 
PDGF  B,  PDGF  SA,  and 
PDGF LA. To insert PDGF B 
coding sequences, pMet was 
digested in the polylinker  with 
XbaI and SacI. This was li- 
gated to a  750-bp XbaI/SacI 
fragment  cut  from  a  pUC 
clone containing PDGF B cod- 
ing sequences inserted at the 
Sinai  site  (S~lnchez  et  al., 
1991).  pMet PDGF-LA con- 
tained  a  610-bp  fragment 
from a pUC clone of PDGF- 
LA, generated by EcoRI di- 
gestion, end filling with Klenow polymerase, and then digesting with XbaI (S~inchez et al., 1991). Coding sequences for PDGF-SA were 
generated by thesame strategy from a pUC clone containing PDGF-SA. pMet was cut with BamHI, end filled with Klenow DNA polymer- 
ase I, and then cut with XbaI before ligation to the above two fragments. All procedures used methods outlined in Maniatis et al. (1982): 
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vector of  interest (9 #g), pSV2neo (1 #g), and pSV2pac (4 #g) to allow selec- 
tion of transfected ceils for resistance to G418  (400 #g/ml; Geneticin; 
Sigma Immunochemicals, St. Louis, MO)and puromycin (10 #g/ml; Geneti- 
cin; Sigma Immunoehemieals). The double transfection and selection pro- 
cedure was utilized to increase the proportion of surviving transfectants ex- 
pressing introduced genes at high levels (Wirth et al.,  1988). Colonies of 
resistant cells (100-200 colonies per 75 mm culture dish) were collected 
and frozen in bulk, without cloning. 
RNA Assays 
Cytoplasmic RNA was isolated as described by Gough (1988). PDGF A and 
B mRNAs were detected in total cytoplasmic RNA by ribonuclease protec- 
tion assay using an RPA II ribonuclease protection assay kit (Ambion Inc., 
Austin, TX). Complete coding sequences for PDGF SA and B, generated 
by polymerase chain reaction (S~lnchez et al.,  1991),  were cloned into 
Bluescribe MI3  + (Vector Cloning Systems, San Diego, CA) and riboprobes 
were transcribed in a 20 #1 reaction using the Riboprobe transcription sys- 
tem (Promega Biotec,  Madison, WI) according to the manufacturer's in- 
structions. After transcription, the DNA template was removed by adding 
1 U of RNase-free  DNase (Promega Biotec) and incubating the mixture for 
a further 15 rain at 37"C. Probes were purified by electrophoresis on a 5% 
polyacrylamide/7 M urea gel as detailed in instructions for the Ambion RPA 
kit. After ribonuclease digestion,  protected RNA fragments were separated 
on the same gel system and detected by autoradiography in comparison with 
Hinfl-digested pBR322  DNA,  end-filled  with Klenow  polymerase I and 
[32p] dATP (Maniatis et al.,  1982). A parallel RNase protection assay was 
carried out using a probe from the glyceraldehyde phosphate dehydrogenase 
gene (Tso et al., 1985) to standardize the amounts of RNA added to the orig- 
inal reactions. 
Protein Assays 
PDGF A and B polypeptides were detected by Western blotting (Ausubel, 
1990). Secreted protein was harvested by incubating 60 mm plates of cells 
overnight in 2 ml of serum-free medium with or without metal ions to in- 
duce PDGF expression.  The medium was collected, and debris removed by 
brief  centrifugation (500 g, 10 min). The supernatant was, for some experi- 
ments, concentrated tenfold in Amicon Centricon 10 microconcentrators, 
by spinning for 1 h at 6,500 rpm in a Sorvall GSA rotor (DuFont,  Newton, 
CT). Control experiments showed that no PDGF was lost during this proce- 
dure.  The remaining cells were washed with PBS, and collected in PBS by 
scraping with a rubber spatula. Cells were washed in PBS, collected by cen- 
trifugation, and resuspended in 100 #1 Laemmli sample buffer (no mercap- 
toethanol) (Laemmli,  1970).  While some extracellular matrix material 
vmuld be collected with the cells after scraping, the two wash/centrifugation 
steps were included to separate all but the more closely associated material 
from the collected ceils. The cell extract was passed through a 26 G needle 
ten times and heated to 98"C for 10 min. Debris was removed by spinning 
the sample for 5 rain in an Eppendorf microcentrifuge (Brinkman Instru- 
ments, Inc., Westbury, NY). Aliquots of cellular and secreted proteins were 
separated by electrophoresis in 15% polyacrylamide  gels containing SDS, 
under non-reducing conditions.  The stacking gel was 6% polyacrylamide. 
The separated proteins were transferred to nitrocellulose  membrane (0.2 
#m) by electroblotting, as described by Towbin et al. (1979). After blocking 
with 1% instant non-fat dry milk powder in TBS (12 mM Tris-HC1, pH 7.4, 
120 mM NaCI) for 2 h at 37"C, filters were incubated with polyclonal anti- 
body specific for either PDGF AA or BB homodimers (rabbit anti-human, 
obtained from G-enzyme Corp., Boston, MA, and diluted to 20/zg/ml in 
blocking buffer). After overnight incubation at 4°C, unbound antibody was 
removed by washing the filter four times in blocking buffer. Filters were then 
incubated with sheep anti-rabbit  IgG coupled to alkaline phosphatase (Sile- 
nus Laboratories, Hawthorn, Australia), diluted 1 in 20,000  in blocking 
buffer. The filters were further developed  to show bound enzyme activity 
using a commercial kit (Immunoselect; Bethesda Research  Laboratories, 
Gaithersburg, MD). 
The standards used were recombinant PDGF SA homodimer expressed 
in E.  coli and PDGF B homodimer expressed in yeast  (Genzyme Corp., 
Boston, MA), diluted in 10 mM acetic acid and 0.1% BSA according to the 
manufacturer's instructions. Prestained protein mixes  (Biorad Laborato- 
ries, Richmond, CA) were used as molecular weight markers. 
For immunofluorescent  labeling, cells were grown on glass coverslips 
overnight in serum-containing medium, with or without metal induction. 
Cells were fixed and antibody treated as described by Thyberg et al. (1990) 
using the same rabbit antibodies directed against PDGF AA and BB as de- 
scribed above, and fluorescein-conjugated  swine anti-rabbit IgG (DAKO- 
PATTS A/S,  Copenhagen,  Denmark).  In these experiments,  antibodies 
against PDGF-AA were used at 10 #g/ml. Fluorescence due to immuno- 
reactive PDGF was viewed in a laser scanning confocal microscope (model 
MRC 500; BioRad Laboratories, Cambridge, MA). Polyclonal antibodies 
prepared in rabbit against mouse laminin were a gift from Ms A. Dalton 
(CSIRO).  Rhodamine-phalloidin for actin labeling was  from Molecular 
Probes, Inc., Eugene,  OR) and was used according to the manufacturer's 
instructions. 
Matrix Studies 
Cells were cleared from attachment to extracellular matrix materials by ly- 
sis with Triton X-100/NI-I4OH as described by Bashkin et al. (1989).  Ma- 
trix remaining was treated with enzymes or other additives  for 60 min at 
37°C  in PBS  (2.5  ml) containing CaC12 (133  #g/ml) and MgC12 (100 
#g/ml). PBS was then removed from the plates. To examine the sizes of pro- 
teins remaining at the surface,  Laemmli sample buffer was added (300 #1 
per 100 mm plate; Laemmli, 1970) and the matrix was dispersed by scrap- 
ing with a rubber spatula.  This material was collected,  and heated at 98°C 
for 10 min. Debris was removed by microfuging and protein in the superna- 
tant was analyzed by polyacrylamide  gel electrophoresis,  carried out under 
nonreducing conditions,  followed by Western blotting as described above. 
The supernatant material, removed after enzyme or other treatment of the 
matrix, was concentrated tenfold. Aliquots were diluted in 3 x  concentrated 
Laemmli sample buffer and heated and analyzed as described above. 35S- 
labeling of sulphated proteoglycans  being deposited into the extracellular 
matrix was carried out as described by Brunner et al. (1991). Sodium [35S] 
sulphate (400 mCi/mmole) was obtained from DuPont. 
Results 
PDGF Production in Transfected Cells 
CHO cells in culture were transfected separately with the 
expression  vectors  pMetPDGF  SA,  pMetPDGF  LA,  and 
pMetPDGF B, together with selectable marker genes as de- 
scribed  in  Materials  and  Methods.  Uncloned,  antibiotic- 
resistant cell populations from each of the three transfections 
(CHO SA, CHO LA, and CHO B, respectively) were tested 
for PDGF  expression  by Western blotting of material as- 
sociated  with cells, and secreted into the medium.  Fig.  2 
shows PDGF homodimers detected for these CHO SA and 
CHO LA cell populations. Untransfected CHO cell samples 
showed no immunoreactive material in either medium or cell 
extracts. CHO SA and CHO LA cell samples were not de- 
tected in Western blots when these were probed with anti- 
body directed against PDGF BB (not shown). In CHO SA 
cultures tested with antibody to PDGF AA, >80 % of the im- 
munoreactive material detected was found in the medium. 
Three protein bands were seen running at 37, 34, and 32 kD 
compared with molecular weight standards, with the smaller 
bands predominating. The lowest band had an electropho- 
retic mobility similar to that of the standard PDGF AA pro- 
duced in E. coli (28.6 kD, running at 32 kD in our gel system) 
(Fig. 2). In some experiments, material of a lower molecular 
weight, corresponding to that of monomer, was also seen. 
Little cell-associated PDGF SA was seen, and that detected 
was larger (39 and 42 kD), indicating that this was unpro- 
cessed or partially processed material. Production of immu- 
noreactive PDGF SA by the CHO SA culture was estimated 
by comparison with the PDGF AA standard at 200-400 ng 
per  106  cells  per  day  following  heavy  metal  induction. 
Amounts of PDGF produced were estimated from four to 
five different samples for this and other cell lines, but provide 
an approximation of relative levels only. Production was not 
rigorously quantitated using a PDGF standard curve. Our 
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cells expressing PDGF SA and LA genes (CHO SA and CHO LA, 
respectively) were tested for the relative localization of immuno- 
reactive PDGF A in cell extracts and secreted into the medium, 
with or without induction of gene expression by heavy metals as 
described in Materials and Methods. Analysis was by Western blot- 
ting after separation of proteins on a nonreducing SDS-polyacryl- 
amide gel. Medium samples are 10/~1  of 10x concentrated material 
(5 % of total collected per 5  x  10  ~ cells); cell extract samples are 
10 #1 (10% of total per 5  x  10  ~ cells). (Lanes A-9 and B-1 ) 20 ng 
PDGF AA; (lanes M) protein markers whose sizes are indicated 
in kD. (A) Lanes I and 2, CHO LA cells, plus and minus induction 
as indicated;  lanes 3 to 6, duplicate  samples for CHO SA cells; 
lanes 7and 8, untransfected CHO cells. (B) Lane 2 and 3 CHO LA; 
lanes 4 and 5, CHO SA. Samples shown are from two gels run in 
parallel. 
Figure 3. Production of PDGF B by CHO B cells. Protein secreted 
into the medium and retained by CHO B cells was collected and 
analyzed as described for Fig. 2, except that antibody specific for 
PDGF BB was used in Western blotting procedures.  (Lane I) 0.5 
ng PDGF BB (recombinant); (lanes 2 and 3) duplicate lanes of me- 
dium  from metal-induced  CHO B cells;  (lane 4)  medium  from 
metal-induced CHO cells (control); (lane 5) metal-induced CHO B 
cells extract. Medium samples were 12/~1 10x concentrated  (6% 
of total collected from 5  x  106 cells); cell extracts were 5 #lsam- 
ples (5% of total from 5  x  106 cells). 
results compare with a previous report of PDGF production 
in  CHO cells at 700  ng/106 cells/d  (Ostman et al.,  1988) 
using a different expression vector. 
In contrast to our results with PDGF SA, a lower level of 
PDGF LA (around 20 ng per 10  ~ cells/d) was detected, ei- 
ther secreted into the medium by or associated with CHO 
LA cells.  Of the  immunoreactive material detected,  more 
was associated with cells than in the medium. The apparent 
molecular weight of  this material (predominantly 42 kD) was 
consistent with it being a partially processed form of PDGF 
LA.  Secreted material was similar to that from CHO SA 
cells,  with the 34-kD form predominant.  (This material is 
difficult to detect in Fig. 2, and was seen only at a low level 
in replicate experiments.) Our estimates of relative produc- 
tion of PDGF SA and LA in transfected cells depend on an 
assumption that the antibody being used detects the LA and 
SA forms with equal efficiency. 
Fig. 3 shows the pattern obtained when CHO B cells were 
examined. Moderate amounts of material reacting with anti- 
body to PDGF BB were detected,  with a  variety of forms 
(predominantly 26 and 38 kD) found to be cell associated, 
while 38-kD material and a series of bands down to 30 kD 
were found in the medium. These can be compared with the 
standard PDGF BB produced in yeast (32 kD). As for Fig. 
2,  CHO cell extracts and medium did not react with anti- 
PDGF BB antibody.  No antibody binding was detected in 
control experiments in which CHO B samples were probed 
with anti-PDGF AA antibody. Total PDGF BB production 
detected in CHO B cells was of the order of 80-120 ng of 
homodimer per  106  cells in  24 h.  Our results differ from 
those reported by Thyberg et al. (1990),  who examined the 
fate of metabolically labeled PDGF BB, produced in CHO 
cells over a 6-h labeling period. They found a higher propor- 
tion of cell-retained (although apparently not cell surface- 
localised) material than reported here. In experiments where 
we  have  cultured  CHO  B  cells  in  the  same,  serum-free 
medium for up to 5  d before harvest, we have found a net 
change in the distribution of PDGF BB between cells and su- 
pernatant, with a greater proportion of immunoreactive ma- 
terial being found in medium after the longer culture period 
(Martins,  R., and M.  Sleigh, unpublished data). This may 
reflect relatively inefficient processing of PDGF BB by CHO 
cells,  and  suggests that the  observed distribution  between 
cells and supernatant (we have not investigated matrix PDGF 
in this context) will depend when sampling occurs. 
RNA being expressed in the three transfected cell cultures 
was examined by RNase protection assay using total cyto- 
plasmic RNA. Fig. 4 shows the results obtained for CHO SA 
and CHO LA cultures. In both cases, approximately tenfold 
induction of RNA resulted from heavy metal treatment of the 
cultures.  High levels of PDGF-specific RNA were also ob- 
served in CHO B cells (results not shown), but in these cells, 
metal induction of the RNA was limited to fivefold. 
The protected region of probe is larger in hybrids with SA 
than with LA RNA. This results in some loss of radioactive 
label from LA compared with SA RNA hybrids. After cor- 
recting for this, the level of PDGF RNA produced by CHO 
SA cells appeared to be no more than fivefold greater than 
that expressed in CHO LA cells. This difference is less than 
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A RNA in CHO SA and CHO 
LA cells.  Ribonuclease pro- 
tection  was  used  to  assess 
PDGF  RNA  levels  in  CHO 
SA (lanes 1 and 2) and CHO 
LA  cells  (lanes  3  and  4). 
RNA from cells with (lanes 2 
and 4) or without (lanes I and 
3) metal induction was incu- 
bated with a radiolabeled probe from the SA gene as described in 
Materials  and Methods.  Amounts of RNA used were first stan- 
dardized to give comparable band intensities following RNase pro- 
tection assay using a GAPDH probe. After RNase digestion of the 
mRNA/probe hybrids, SA RNA yields a protected fragment of 620 
bases and LA a fragment of 520 bases, since the LA gene diverges 
from the SA transcript used as a probe beyond exon 5 sequences. 
would be expected from the results shown in Fig. 2, where 
10-20-fold more immunoreactive PDGF was detected for 
CHO SA than for CHO LA cultures. 
Localization by Immunofluorescence of  PDGF  LA and 
B Homodimers Made in CHO Cells 
Previous published reports have suggested that in NIH3T3 
and COS 7 cells, the primary site for PDGF LA localization 
is cellular (La Rochelle et al.,  1990a; Ostman et al.,  1991). 
In Fig. 2, we thus would have expected to find more PDGF 
LA in cell extracts than we observed. In addition, there is 
an apparent discrepancy between total PDGF LA protein de- 
tected relative to PDGF SA, given the ratios of RNA produc- 
tion in the two cell types, as discussed above. This led us to 
further examine the location of immunoreactive PDGF in 
producing cells by fluorescence microscopy. The results are 
shown in Fig. 5. Some immunoreactive material was evident 
associated with CHO SA cells (Fig.  5  b) as would be ex- 
pected from published data and the results of Fig. 2. No ma- 
terial was detected in these samples at the basal level of the 
cells where they contact the culture dish (Fig. 5, upper right 
frame of b). For PDGF LA, on the other hand, most of the 
fluoresce  detected was  found in  this  plane  (Fig.  5  c). 
These findings are consistent with immunoreactive material 
ass~!ated either with the basal surface of producing cells, 
or depbsited into extracellular matrix. Since the material de- 
tected appeared to spread beyond the cell boundaries, the lat- 
ter appears more likely. This was further explored by stain- 
ing equivalent cultures for the matrix protein laminin and for 
PDGF A  in parallel.  Coverslips from PDGF LA cultures 
were stained with rabbit anti-mouse laminin polyclonal anti- 
body, followed by FITC-labeled anti-rabbit antibody. These 
results confirm that immunofluorescent material produced 
by CHO LA cells has a similar localization to laminin at the 
cell-plate  interface,  suggesting  a  matrix  localization  for 
PDGF LA (Fig.  5, f  and g). 
As predicted from the Western assays (Fig. 2), and com- 
pared  with the  total  amount of fluorescence detected for 
CHO LA cells, only small amounts of immunoreactive mate- 
rial were found associated with CHO SA and LA cells. In 
both cases this was located in granular regions within the 
cells. CHO cells containing no PDGF LA gene gave similar 
staining for laminin, but no staining with the PDGF antibody 
(not shown). 
A  somewhat similar pattern to that described for PDGF 
LA was seen for PDGF B-expressing ceils (Fig. 5 e). The 
bulk of immunoreactive material detected was in a  similar 
location to that shown for PDGF LA in Fig. 5 (c and g), pre- 
surnably in or on the matrix below cells. For both PDGF LA 
and B, examination of transfected cells that had not under- 
gone  induction  indicated  similar  relative  distribution  of 
fluorescence between matrix and cells as  seen in induced 
cells. However, the levels detected were lower, as expected. 
Analysis of Matrix-Associated PDGF  LA 
To  expose underlying  matrix  material  and  examine  how 
PDGF was bound within it, CHO LA cells were lysed by 
treatment with Triton X-100 and NI-LOH, as described by 
Bashkin et al. (1989). PDGF LA was shown by fluorescence 
microscopy to be retained in the attached matrix after this 
treatment (data not shown). 
The matrix material was extracted with Laemmli sample 
buffer, and PDGF LA dimers present were detected by West- 
ern blotting. As shown in Fig. 6 A, substantial amounts of 
PDGF LA were observed, with sizes of homodimers in the 
range 48-34 kD. The major bands were 40 and 44 kD.  No 
significant  immunoreactive  material  of higher  molecular 
weight was present. Little if any fully processed material (30 
kD) was detected. The matrix material prepared by cell lysis 
with Triton and shown in Fig. 6 reveals a different although 
overlapping pattern of  protein bands compared with material 
displayed from cell extracts (Fig. 2, lane A/). This indicates 
effective separation of cellular and extracellular material by 
the procedures used. The relative amounts of material found 
in the matrix extracts compared with cell extracts are also 
consistent with the distribution of material observed in im- 
munofluorescence  studies.  Assuming  that  our  extraction 
method liberates all PDGF for detection by Western blotting, 
the results shown in Fig. 6 indicate PDGF LA equivalent to 
'~120 ng of the PDGF SA standard localized in the matrix 
by  10  ~ cells  in  24  h  under  conditions  where  20  ng  of 
equivalent cell-associated material was detected. The total 
of ,o700 ng produced per plate of 5  x  10  ~ cells compared 
with 1-2 #g for CHO SA under equivalent conditions is con- 
sistent with the relative amounts of PDGF A  mRNA pro- 
duced by the two cell types (Fig. 4).  As stated previously, 
estimation of PDGF levels involves several assumptions and 
is useful as a guide only. 
Since the Triton method lyses cells during their removal, 
there is some chance that PDGF contained within cells or 
associated with the cell surface may contaminate the matrix 
during the procedure (Bashkin et al.,  1989; Brunner et al., 
1991). An alternative approach is the use of  2 M urea, which 
removes the cells intact (Gospodarowicz et al.,  1983). This 
method was tested as a control for the Triton procedure. The 
urea method was not particularly effective in CHO LA cell 
removal using published conditions and even with more ex- 
tended urea treatment,  cells and cell debris remained as- 
sociated with the surface. This was demonstrated by staining 
for actin on coverslip surfaces with rhodamine-phalloidin 
after  removal  of cells  by  either  Triton/NH4OH  or  urea 
treatment.  Actin  staining  was  detected on urea-generated 
matrices  but  not  on  those  generated  by  Triton/NtLOH 
treatment. A third approach to cell removal, use of EDTA, 
was completely ineffective in detaching CHO LA cells from 
cultured surfaces in our experiments. A comparison of the 
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pared by Triton cell lysis. Matrix deposited by CHO LA cells was 
exposed by lysis of cells using the Triton procedure  described  in 
Materials and Methods.  PDGF was detected by Western blotting. 
(A) Effects of heparin. Matrix was incubated (60 min, 37°C) in 2.5 
ml PBS containing Ca  :+ and Mg  :+ with or without heparin (5/~g/ 
ml). (Lane $1 ) Immunoreactive PDGF A released into the superna- 
tant by heparin.  8% of material released into the supernatant by 5 
x  106 ceils was loaded after concentration.  (Lane M/) Material 
remaining in the matrix after this treatment (5 % of the total mate- 
rial deposited by 5  x  106 cells loaded).  (Lanes $2 and M2) PDGF 
A in supernatant and matrix after incubation with buffer alone. (B) 
Effect of enzymes with heparin.  The left panel shows material re- 
maining  in matrix after treatment  (1.7% of total from 5  x  106 
cells loaded).  The fight panel shows supernatant  samples (4 % of 
total loaded). Samples shown are from two gels run in parallel. (M) 
Molecular weight markers (sizes shown in kD); (S) 10 ng standard 
PDGF AA; (1) no additives; (2) collagenase (C-0773, 100 #g/ml) 
+ heparin (5/zg/ml); (3) collagenase (C-0773, 100 #g/ml); (4) col- 
lagenase (C-9407, 25 #g/ml) +  heparin (5 #g/ml);  (5) collagenase 
(C-9407, 25 #g/ml); (6) trypsin (50 #g/ml) +  heparin (5 #g/ml); 
(7) trypsin (50 #g/mi). (C) Effect of  chondroitin ABC lyase. Matrix 
was incubated (60 min, 37°C) in 2.5 ml of 0.3 M Tris HCI, pH 8.0, 
PDGF content of matrix exposed by the urea and Triton pro- 
cedures indicated no significant differences in immunoreac- 
five material (amount or sizes) detected by Western blotting. 
The Triton procedure was therefore used in all experiments 
for exposing extracellular matrix. 
Mode of  Attachment of PDGF LA in the Matrix 
Studies  on the  differences of fate between PDGF  SA and 
PDGF LA have suggested that the basic COOH-terminal ex- 
tension in PDGF LA is responsible for cell attachment of  this 
species (LaRochelle et al.,  1990a,b;  Ostman et al.,  1991). 
Attachment to cellular heparan  sulphate proteoglycan has 
been proposed for the COOH-terminal peptide, and it was 
implied that matrix attachment of the LA species might be 
mediated in the same way (Raines and Ross, 1992; Khachig- 
ian and Chesterman,  1992).  The role of heparan sulphate 
binding in PDGF matrix attachment was tested by incubating 
PDGF LA-containing matrix exposed by Triton lysis either 
with an excess of heparin (Sigma Immunochemicals; 5 #g/ 
ml) as a binding competitor, or heparitinase (0.1 U/ml; EC 
4.2.2.8;  Sigma  Immunochemicals),  which  should  digest 
heparan sulphate and liberate carbohydrate-bound material 
(Bashkin et al.,  1989). 
Heparin caused release of considerable amounts of im- 
munoreactive material into solution (Fig. 6 A), with a corre- 
sponding decrease in the amount of material remaining at the 
plate surface. Released material was of similar size to that 
detected in the matrix, i.e., 34-45 kD. Heparitinase gener- 
ally  induced  no  release of PDGF  (results  not  shown)  al- 
though in some experiments, a very small amount of mate- 
rial,  running  at 40  kD  and  above,  was  detectable  in  the 
supernatant.  In  separate  experiments  (not  shown)  it  was 
demonstrated that the heparitinase treatment used in Fig. 6 
could  release  20%  of  incorporated  35S-labeled  sulphate 
from matrix into the medium during the incubation period. 
Further experiments, in which the heparitinase concentra- 
tion was increased up to 50-fold, did not result in any greater 
loss of PDGF A  from the matrix (results not shown). 
Previous  studies  examining attachment of bFGF in  ex- 
tracellular matrix have suggested that this growth factor is 
laid down during matrix deposition and that only surface ma- 
teriai may be accessible to enzymes or other competitors of 
binding  (Vlodavsky et al.,  1991).  We used bacterial  col- 
lagenase to partially degrade the matrix in an attempt to in- 
18 mM Na acetate,  aprotinin (100 Kallikrein inhibitor  U/ml) and 
chondroitin ABC lyase (0, 0.03, 0.1 U/mi, shown as samples 1, 2, 
and 3, respectively).  Material  remaining in the matrix (M) or re- 
leased into the supernatant (S) was measured by Western blotting. 
M samples represent 7 % and S samples 8 % of total material from 
a plate of 5  x  106 cells. 
Figure 5. Immunolocalization of  PDGF A and B in expressing CHO cells. The cell and matrix distribution of  PDGF B, SA, and LA produced 
in transfected CHO cells was examined by laser confocal microscopy as described in Materials and Methods. The distribution of laminin 
was included as a control (f). For each panel, a-g, the top left box shows the phase contrast view of the cells, while top right,  bottom 
left and bottom right show progressive scanning for fluorescence due to immunoreactive material from the level of  cell-plate contact through 
to the top of the cells.  (a) Untransfected CHO cells;  (b) CHO-SA; (c) CHO-LA, all using anti-PDGF  AA antibody. (d) Untransfected 
CHO ceNs; (e) CHO-B cells, both using first antibody directed against PDGF-BB; (f) CHO LA cells using anti-laminin antibody;  (g) 
CHO LA cells tested in parallel, using anti-PDGF AA antibody. All cells pictured have undergone metal induction as described in Materials 
and Methods. 
Kelly et al. PDGF  in the ExtraceUular  Matrix  1159 crease the  accessibility of matrix-bound growth  factor to 
other agents. Preliminary experiments (not shown) were car- 
ried out to measure the effects of matrix exposure to increas- 
ing amounts of  collagenase (C  -9407, ti  s  sue culture grade, 1.6 
U/#g, containing 0.1% contaminating protease; Sigma Im- 
munochemicals). Only at the highest levels (25-50/zg/ml) 
was immunoreactive PDGF A detectable in the supernatant 
in the absence of heparin,  with no significant loss of total 
PDGF from the matrix under these conditions. The PDGF 
released appeared from this  and other experiments to be 
smaller than bound forms, as identified on nonreducing gels, 
with 30-34 kD material predominating in the supernatant. 
Collagenase  treatment  did  not  increase  the  amount  of 
PDGF LA released from the matrix by heparin, but it did 
reduce the size of the material released, from 35-46 kD, to 
30-35 kD (Fig. 6, compare A, lane $1, with B, lane $4). This 
cleavage of immunoreactive species appeared to be due to 
contaminating protease in  the collagenase preparation.  A 
more highly purified collagenase (C-0773;  Sigma Immu- 
nochemicals) did not cause the same cleavage of heparin- 
released material (Fig. 6 B, lane 2). As well, the degrading 
effects of crude collagenase were inhibited by 2 mM EDTA 
(an inhibitor of metalloproteinases including collagenase; 
Seifter and Harper, 1971) but not by the more general pro- 
tease inhibitor PMSF, tested at 0.5 mM (results not shown). 
This suggests that the active component in the collagenase 
preparation may be a contaminating metaUoproteinase. Treat- 
ment of PDGF LA-containing matrix with trypsin was able 
to directly liberate PDGF, as described previously for bFGF 
(Saksela and  Rifkin,  1990).  Cleavage products of similar 
size to those seen with collagenase plus heparin were pro- 
duced early, but longer treatment with trypsin led to degra- 
dation and disappearance of immunoreactive PDGF from 
both matrix and supernatant in the presence or absence of 
heparin, as shown in Fig. 6 B. Taken together these results 
suggest that the release by proteases shown in Fig. 6 is likely 
to be due to degradation of the PDGF itself, with potential 
cleavage sites becoming available principally after dissocia- 
tion of PDGF from the matrix by heparin. 
The mode of attachment of PDGF LA was further tested 
by  incubating  Triton-generated  matrix  with  chondroitin 
ABC  lyase (EC 4.2.2.4;  Sigma Immunochemicals).  This 
treatment was effective in liberating a small proportion of at- 
tached PDGF LA. Little increase in release was seen with 
increased amounts of enzyme (Fig. 6 C). These results sug- 
gest a role for the glycosaminoglycan moieties of the chon- 
droitin sulphate or dermatan types in attachment of PDGF 
LA.  Competition  studies  with chondroitin sulphate  A,  B 
(dermatan sulphate), C, and keratan sulphate revealed that 
none  of  these  glycosaminoglycans  liberated  detectable 
amounts of PDGF from the matrix (results not shown) under 
conditions where heparin (as shown in Fig. 6 A) released up 
to 50%  of bound material. 
Matrix Association of  PDUF  B 
Immunofluorescence studies shown in Fig. 5 indicated that 
in CHO B cultures considerable amounts of PDGF were de- 
posited into matrix material below cells. Material remaining 
on the plate after Triton lysis was examined using similar ap- 
proaches to those outlined above for PDGF LA. Fig. 7, ma- 
trix lane 1 shows material specifically reactive with an anti- 
body  directed  against  PDGF  B  homodimer,  following 
extraction of Triton-generated matrix deposited by CHO B 
cells. The major polypeptides observed were of 31, 35, and 
38 kD. These can be compared with a major cell-retained 
species  of 38  kD,  as  shown  in  Fig.  3  (minor  species  of 
smaller size were also observed here). Incubation of CHO 
B matrix with heparin (Fig. 7, lane 5) released material of 
similar sizes, i.e., 38,  34, and 30 kD, with a minor species 
of 48 kD. When heparin and crude collagenase treatments 
were combined, released forms were reduced to 26 and 30 
kD,  with  no overall increase in  immunoreactive material 
released. This is likely to reflect cleavage of released PDGF 
by contaminating proteases in the collagenase, as discussed 
above.  None  of  the  treatments  appeared  to  decrease 
significantly the total levels of PDGF B detected in the ma- 
trix,  indicating incomplete extraction of the growth factor 
deposited by these cell cultures. A minimum of 80 ng of de- 
posited material was detected per 106 cells over two days in 
these experiments, with the actual amount in the matrix al- 
most certainly higher. This suggests that matrix-bound mate- 
riai represents at least 40 % of the PDGF B made by CHO 
B cells, under the culture conditions described. 
In these experiments, there was some leakage of material 
(38  kD)  from Triton-prepared matrix  incubated  in  PBS, 
Figure 7. Release of PDGF B 
from extracellular matrix pre- 
pared by Triton lysis of cells. 
Matrix deposited by CHO-B 
cells was exposed by the Tri- 
ton procedure and incubated 
as described for Fig. 6 except 
the  following additions were 
made:  (lane  1)  collagcnase 
(C-9407, 50/~g/ml);  (lane 2) 
coUagenase (C-9407, 50  #g/ 
ml)  +  heparitinase  (0.1 U/ 
ml); (lane 3) heparitinase (0.1 
U/ml); (lane 4) heparin (5 #g/ 
nil)  +  collagenase  (C-9407, 
50 #g/ml); (lane 5) heparin (5 #g/ml); (lane 6) no additives; (lane 7) matrix from CHO cells, no additives. (M) molecular weight markers, 
sizes in kD.  Residual matrix samples (left) were 10 #1, representing 3.3% of the total matrix per 5  ×  106 cells; supernatant samples 
(right) were 10 #1 (10× concentrated) representing 4% of the total supernatant from the same plate. 
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it appears from these results that PDGF B deposited into the 
matrix by expressing cells can be partially released from its 
matrix  attachment  by  addition  of  heparin,  but  not  by 
heparitinase.  Other  glycosaminoglycans (chondroitin sul- 
phate A, C, dermatan sulphate, and keratan sulphate) were 
unable to displace significant amounts of PDGF B from the 
matrix  at  concentrations  where  heparin  was  effective in 
releasing bound material (results not shown). 
Discussion 
Since the genes encoding PDGF B and the two forms of 
PDGF  A  were  first isolated there has been considerable 
speculation on the relative biological roles of the three poly- 
peptides they encode. The identification of two PDGF recep- 
tor subunits (PDGFR ot and t)  has revealed one level at 
which PDGF action may be controlled. Differential expres- 
sion of the two receptor types may change the response of 
the cells to exogenous PDGF since the ct receptor binds both 
A and B chains of PDGF, while the/~ receptor recognizes 
only the B form (Matsui et al., 1989; Hart et al., 1988; Hel- 
din et al.,  1988). 
The expression of recombinant PDGF A  and B homo- 
dimers has led to greater understanding of their relative bio- 
logical  properties,  with  PDGF  B  demonstrating  greater 
transforming activity for most target cells and A being more 
readily processed for secretion (Beckmann et al., 1988; La- 
Rochelle et al., 1990b).  Initial work with the product of the 
exon 6-containing PDGF A mRNA- PDGF LA- suggested 
that it may be reduced in its capacity for processing and secre- 
tion from cells compared with SA. More recently, it has been 
shown that the additional basic COOH-terminal sequence 
present in this form of PDGF A is associated with retention 
of the polypeptide by the cell (LaRochelle et al.,  1990a,b; 
Ostman et al., 1991). A peptide identical to this COOH-ter- 
minal region is able to compete with and displace attached 
forms of PDGF and other growth factors (Khachigian et al., 
1992; Raines and Ross, 1992) although at least in the former 
study, very high concentrations of peptide were required. 
PDGF LA appears to be produced in most or all PDGF 
A-synthesizing cells, and to make up no more than 5-10% 
of the total PDGF A  produced (Matoskova et al.,  1989; 
Young et al.,  1990;  S,~nchez, A., C.  Chesterman and M. 
Sleigh, manuscript in preparation). This would suggest that 
this moiety has little relative biological relevance, except in 
circumstances where it may accumulate to high levels. This 
could occur by retention and concentration of  active material 
within cells, at the cell surface (LaRochelle et al.,  1990a; 
Ostman et al., 1991) or in an extracellular depot such as the 
matrix. The results described in this paper exemplify this last 
possibility. As suggested (Raines and Ross, 1992; Khachig- 
ian and Chesterman, 1992), progressive deposition of PDGF 
LA into subcellular matrix (and also PDGF B, from results 
presented here) provides the potential for substantial amounts 
of growth factor to be held in preformed storage pools. This 
deposited growth factor is available for subsequent mobiliza- 
tion, possibly by the release of appropriate enzymes from 
damaged or otherwise activated cells. 
The Triton/NI-LOH method used here to lyse cells and 
expose subcellular matrix may result in residual cell mem- 
brane material or material bridging cells and matrix remain- 
ing attached to the matrix through subsequent washing. Al- 
ternatively, material released from cells during lysis may 
become matrix-associated during the procedure. A further 
difficulty in clearly separating matrix and cellular material 
for study comes from the possible inclusion of some residual 
matrix or bridging material in the  scraped  cell  samples. 
What evidence supports the idea that PDGF is deposited into 
matrix as it is synthesized? 
Firstly, both the quantities (for PDGF LA) and size distri- 
butions (for both LA and B) of species detected in the matrix 
samples compared with cell extracts indicate that the proce- 
dures we have used have been largely successful in separat- 
ing matrix and cellular material. Secondly, the laser confocal 
microscope studies on PDGF LA cells shown in Fig. 5 indi- 
cate a PDGF distribution spreading beyond the boundaries 
of the producing cells, to an even greater extent than that of 
the matrix protein laminin. The relative distributions of im- 
munoreactive material between cells and underlying mate- 
rial seen by microscopy are consistent with the results from 
Western analysis. Since a similar localization was found for 
PDGF LA and the matrix protein laminin, it is highly likely 
that material examined in Triton cell culture extracts and 
visualized by fluorescence studies has matrix localization. 
Finally, we have examined release of PDGF from our matrix 
preparation by salt and have found that less than 20 % of de- 
posited PDGF B  (and a  similar amount of PDGF  A)  is 
released by NaCI concentrations as high as 2 M  (Vander- 
mark,  S., C.  Chesterman and M.  Sleigh, unpublished re- 
suits).  Since PDGF and other growth factors are released 
from heparin-sepharose columns by much lower NaC1 con- 
centrations,  our results  indicate that PDGF  is embedded 
within the matrix and possibly interacting with other matrix 
components rather than exposed at the surface (Vlodavsky 
et al.,  1987). 
Likely parallels to PDGF LA and B matrix attachment are 
retention of thrombin, bFGF, and TGF~/in matrix and at the 
cell surface through binding to proteoglycans (Bar-Shavit et 
al., 1989; Vlodavsky et al., 1991; Andres et al., 1992). The 
characteristics of binding are different in each case, with at- 
tachment primarily through the glycosaminoglycans  in some 
cases (bFGF, thrombin) and through the proteoglycan pro- 
tein cores in others (TGF/$) (Bar-Shavit et al., 1989; Wight 
et al.,  1992). 
It has been proposed previously that the 18 amino acid ba- 
sic COOH-terminal peptide of PDGF LA was attached at 
cell surfaces (and perhaps also to matrix) through associa- 
tion with the heparan sulphate moieties of heparan sulphate 
proteoglycans (Raines and Ross,  1992;  Khachlgian et al., 
1992).  This was supported by release of the peptide with 
heparitinase and competition by heparin for its binding. In 
our studies with PDGF polypeptides synthesized by CHO 
cells, we have found heparitinase to be ineffective in releas- 
ing bound growth factor, indicating an association in the ma- 
trix that is more complex than attachment to heparan sul- 
phate alone. 
Some bound PDGF LA was released from matrix prepara- 
tions by chondroitin ABC lyase. Chondroitin sulphates were 
ineffective although the more highly charged heparin was 
very effective in displacing PDGF from its attachment sites. 
Our results raise the possibility that while part of the attach- 
ment of PDGF LA and B involves chondroitin or dermatan 
sulphate residues, the binding to these moieties is stabilized 
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charge neutralizing effect of heparin (Kjell6n and Lindahl, 
1991). Thus, PDGF appears to share some features of cell 
surface/matrix attachment with thrombin and bFGF and per- 
haps also TGF3. 
For  bFGF, low affinity binding to proteoglycans  is re- 
quired for growth factor activity, but this seems unlikely to 
be the case for PDGF. PDGF SA, with no apparent receptor- 
independent cell binding  activity, has a  somewhat higher 
affinity for the PDGF receptor than PDGF LA and has ac- 
cordingly greater biological effects (Ostman et al., 1989). In 
addition Rapraeger et al.  (1991) have shown that sulphated 
heparan is not essential  for receptor-mediated  activity  of 
PDGF, unlike the situation for bFGF (Yayon et al.,  1991). 
This suggests that at least for B-containing forms of PDGF 
(PDGF LA was not examined in these studies),  surface at- 
tachment is not a prerequisite for high affinity binding in the 
same way that it is for bFGF. The significance of the occur- 
rence of cell-binding forms of PDGF B and presumably also 
LA, may thus depend more on their ability to accumulate in 
the matrix than on their cell attachment properties. Zerwes 
and Risau  (1987)  have described  preferential secretion  of 
PDGF from the basal surface of endothelial ceils. While the 
PDGF examined in their experiments was apparently of the 
soluble rather the cell-binding form, such directional secre- 
tion could assist in establishing extracellular stores of PDGF 
in vivo. 
Previous studies (Khachigian et al., 1992; Khachigian and 
Chesterman,  1992; Raines and Ross,  1992) have pointed to 
overlapping mechanisms of attachment of PDGF species in 
the matrix and at the cell surface. In 3T3 and COS cells, a 
higher  proportion  of  PDGF  expressed  from  introduced 
genes was  found to be cell associated  (LaRochelle  et al., 
1991; Ostman et al., 1991) than has been detected for CHO 
cells (this work and Ostman et al., 1988). Since in all of these 
studies there is considerable overlap in the sizes of PDGF 
species found to be cell associated and reported to be matrix 
associated,  it seems unlikely that differential processing  is 
responsible for these localization effects. A possible explana- 
tion may be differences between cell types in the amounts 
and distribution of proteoglycans  and other molecules in- 
volved in PDGF sequestration. Further detailed work on the 
identity of PDGF-binding matrix and cell surface molecules 
will be ne~ed to clarify this point. 
The  CHO  and  other  recombinant  cells  used  to  study 
PDGF distribution all express PDGF at higher levels than do 
normal  producers,  e.g.,  endothelial  and vascular smooth 
muscle cells. Examination of the distribution of PDGF spe- 
cies made by normal producer cell types will be important 
to assess the true importance of matrix deposition of PDGE 
Of particular interest  will be  to  examine  localization  of 
PDGF in human arteries. Wren et al.  (1986) reported that 
vascular smooth  muscle cells responded to mitogenic  and 
chemotactic factors deposited onto the culture dish by vascu- 
lar endothelial  and smooth muscle cells. In circumstances 
such as balloon  angioplasty of arteries, damaged cells re- 
lease enzymes such as proteases or heparanases (Godder et 
al., 1991; Saksela and Rifkin,  1990) which could cleave at- 
tached PDGF and other growth factors from the matrix. This 
may be an important step in the subsequent activation of vas- 
cular smooth  muscle ceils for migration and proliferation 
which contributes to restenosis  at the site of damage. 
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